JP2006501249A - ワクチン - Google Patents

ワクチン Download PDF

Info

Publication number
JP2006501249A
JP2006501249A JP2004532301A JP2004532301A JP2006501249A JP 2006501249 A JP2006501249 A JP 2006501249A JP 2004532301 A JP2004532301 A JP 2004532301A JP 2004532301 A JP2004532301 A JP 2004532301A JP 2006501249 A JP2006501249 A JP 2006501249A
Authority
JP
Japan
Prior art keywords
immunogen
vaccine
sequence
human
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004532301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501249A5 (enExample
Inventor
エリス，ジョナサン，ヘンリー
アシュマン，クレア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220211A external-priority patent/GB0220211D0/en
Priority claimed from GB0304672A external-priority patent/GB0304672D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2006501249A publication Critical patent/JP2006501249A/ja
Publication of JP2006501249A5 publication Critical patent/JP2006501249A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2004532301A 2002-08-30 2003-08-28 ワクチン Pending JP2006501249A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0220211A GB0220211D0 (en) 2002-08-30 2002-08-30 Vaccine
GB0304672A GB0304672D0 (en) 2003-02-28 2003-02-28 Vaccines
PCT/GB2003/003729 WO2004019975A2 (en) 2002-08-30 2003-08-28 Il-14 vaccine for the treatment of asthma and atopic disorders

Publications (2)

Publication Number Publication Date
JP2006501249A true JP2006501249A (ja) 2006-01-12
JP2006501249A5 JP2006501249A5 (enExample) 2006-06-15

Family

ID=31980002

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004532301A Pending JP2006501249A (ja) 2002-08-30 2003-08-28 ワクチン
JP2004532296A Pending JP2006503018A (ja) 2002-08-30 2003-08-28 ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004532296A Pending JP2006503018A (ja) 2002-08-30 2003-08-28 ワクチン

Country Status (6)

Country Link
US (1) US20060104943A1 (enExample)
EP (2) EP1534323A2 (enExample)
JP (2) JP2006501249A (enExample)
AU (2) AU2003259374A1 (enExample)
CA (2) CA2496948A1 (enExample)
WO (2) WO2004019975A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509321A (ja) * 2006-11-13 2010-03-25 セラヴァック ファーマスウティカルズ エイ ビー 種々の炎症状態の治療用の新規な組成物
JP2021525726A (ja) * 2018-05-29 2021-09-27 ネオヴァクス 異常なｉｌ−４および／またはｉｌ−１３の発現または活性に関連する疾患を治療するためのｉｌ−４および／またはｉｌ−１３を含む免疫原性産物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101073590B1 (ko) * 2003-07-15 2011-10-14 메디뮨 리미티드 Ｉｌ-13에 대한 인간 항체 분자
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
WO2008109957A1 (en) * 2007-03-15 2008-09-18 Hunter Immunology Limited Method for determining suitability of treatment for asthma or chronic airways disease
EP2117586B1 (en) * 2007-03-15 2018-08-08 Hunter Immunology Pty Ltd Treatment or prophylaxis of asthma
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
AU2022215119A1 (en) * 2021-01-29 2023-08-17 Bayer Animal Health Gmbh Vaccine composition for breaking self-tolerance

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
EE200100552A (et) * 1999-04-23 2002-12-16 Pharmexa A/S Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks
EE200200025A (et) * 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
WO2001034645A2 (en) * 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
IL155282A0 (en) * 2000-10-18 2003-11-23 Glaxosmithkline Biolog Sa Vaccines
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
CA2496409A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509321A (ja) * 2006-11-13 2010-03-25 セラヴァック ファーマスウティカルズ エイ ビー 種々の炎症状態の治療用の新規な組成物
JP2021525726A (ja) * 2018-05-29 2021-09-27 ネオヴァクス 異常なｉｌ−４および／またはｉｌ−１３の発現または活性に関連する疾患を治療するためのｉｌ−４および／またはｉｌ−１３を含む免疫原性産物
JP7291729B2 (ja) 2018-05-29 2023-06-15 ネオヴァクス 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物

Also Published As

Publication number Publication date
AU2003260748A8 (en) 2004-03-19
AU2003260748A1 (en) 2004-03-19
WO2004019979A3 (en) 2004-07-08
CA2496607A1 (en) 2004-03-11
WO2004019979A2 (en) 2004-03-11
CA2496948A1 (en) 2004-03-11
AU2003259374A8 (en) 2004-03-19
WO2004019975A3 (en) 2004-07-08
AU2003259374A1 (en) 2004-03-19
JP2006503018A (ja) 2006-01-26
EP1534329A2 (en) 2005-06-01
US20060104943A1 (en) 2006-05-18
EP1534323A2 (en) 2005-06-01
WO2004019975A2 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
JP6938487B2 (ja) ワクチン
JP4238031B2 (ja) ワクチン
JP2006503017A (ja) Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用
EA015551B1 (ru) Конъюгатные вакцины
CN105120892B (zh) 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物
KR20140006115A (ko) 바리셀라 조스터 바이러스 백신
EA014165B1 (ru) Пневмококковая полисахаридная конъюгатная вакцина
JP2008019262A (ja) Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのための免疫原性組成物
WO2007113633A2 (en) Immunogenic compositions comprising cat allergen fel dl
TW201309327A (zh) 疫苗
AU2002233560A1 (en) Vaccine
JP2006503018A (ja) ワクチン
JP2022513452A (ja) 融合によって修飾されたｃｍｖのウイルス様粒子
US20070048261A1 (en) Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
JP2019515957A (ja) イヌアトピー性皮膚炎の治療
KR20020084841A (ko) Ｉｌ5 활성을 다운-조절하는 방법
JP2011057679A (ja) ナイセリアＮｓｐＡタンパク質をリフォールディングする方法
WO2004052395A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
JP2002532433A (ja) インフルエンザ菌由来の少なくとも２つの抗原を含む、疾病予防のための多成分ワクチン
JP2022544407A (ja) 免疫原性組成物
RU2766292C1 (ru) Состав вакцины против covid-19
WO2025077785A1 (zh) 一种抗脑膜炎球菌的免疫组合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100209